Cronos Group Inc (NASDAQ:CRON) Given Consensus Rating of “Hold” by Brokerages

Share on StockTwits

Cronos Group Inc (NASDAQ:CRON) has been given a consensus rating of “Hold” by the sixteen ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $17.71.

CRON has been the subject of several research reports. ValuEngine raised Cronos Group from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd. MKM Partners assumed coverage on shares of Cronos Group in a report on Thursday, September 19th. They issued a “neutral” rating and a $14.00 price target for the company. Piper Jaffray Companies reduced their price objective on shares of Cronos Group from $18.00 to $12.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Stifel Nicolaus upgraded Cronos Group from a “hold” rating to a “buy” rating and decreased their price objective for the stock from $16.50 to $14.00 in a research report on Friday, October 18th. Finally, Zacks Investment Research downgraded shares of Cronos Group from a “buy” rating to a “hold” rating in a research report on Wednesday, November 13th.

CRON opened at $6.71 on Monday. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of -83.88 and a beta of 3.20. Cronos Group has a 1-year low of $6.04 and a 1-year high of $25.10. The business has a 50 day moving average price of $7.67 and a two-hundred day moving average price of $11.77.

Cronos Group (NASDAQ:CRON) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. Cronos Group had a return on equity of 31.88% and a net margin of 4,086.41%. The company had revenue of $10.10 million for the quarter, compared to analysts’ expectations of $10.42 million. As a group, research analysts predict that Cronos Group will post -0.13 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. Captrust Financial Advisors grew its stake in Cronos Group by 7,925.0% in the 2nd quarter. Captrust Financial Advisors now owns 1,605 shares of the company’s stock valued at $26,000 after buying an additional 1,585 shares during the last quarter. Commonwealth Bank of Australia bought a new stake in Cronos Group during the second quarter valued at about $29,000. US Bancorp DE boosted its holdings in Cronos Group by 90.9% during the second quarter. US Bancorp DE now owns 2,100 shares of the company’s stock valued at $34,000 after acquiring an additional 1,000 shares during the period. Resources Investment Advisors LLC. bought a new stake in Cronos Group during the second quarter valued at about $38,000. Finally, Executive Wealth Management LLC grew its position in shares of Cronos Group by 330.6% in the second quarter. Executive Wealth Management LLC now owns 2,670 shares of the company’s stock valued at $43,000 after purchasing an additional 2,050 shares during the last quarter. Institutional investors and hedge funds own 11.60% of the company’s stock.

About Cronos Group

Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations ?MMPR?. The firm typically invests in companies based in Canada.

Featured Article: Stochastic Momentum Index (SMI)

Analyst Recommendations for Cronos Group (NASDAQ:CRON)

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Founders Capital Management Sells 500 Shares of Weingarten Realty Investors
Founders Capital Management Sells 500 Shares of Weingarten Realty Investors
Founders Capital Management Has $28,000 Stock Holdings in Genworth Financial Inc
Founders Capital Management Has $28,000 Stock Holdings in Genworth Financial Inc
Comcast Co.  Stake Boosted by 10 15 Associates Inc.
Comcast Co. Stake Boosted by 10 15 Associates Inc.
10 15 Associates Inc. Has $2.27 Million Stake in Air Products & Chemicals, Inc.
10 15 Associates Inc. Has $2.27 Million Stake in Air Products & Chemicals, Inc.
10 15 Associates Inc. Has $2.86 Million Stock Holdings in CVS Health Corp
10 15 Associates Inc. Has $2.86 Million Stock Holdings in CVS Health Corp
10 15 Associates Inc. Grows Stock Holdings in Canadian Pacific Railway Ltd
10 15 Associates Inc. Grows Stock Holdings in Canadian Pacific Railway Ltd


© 2006-2020 Ticker Report